Cargando…
Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts
Breast tumors comprise an infrequent tumor cell population, termed breast tumor initiating cells (BTIC), which sustain tumor growth, seed metastases and resist cytotoxic therapies. Hence therapies are needed to target BTIC to provide more durable breast cancer remissions than are currently achieved....
Autores principales: | Gwynne, William D, Hallett, Robin M, Girgis-Gabardo, Adele, Bojovic, Bojana, Dvorkin-Gheva, Anna, Aarts, Craig, Dias, Kay, Bane, Anita, Hassell, John A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458271/ https://www.ncbi.nlm.nih.gov/pubmed/28404880 http://dx.doi.org/10.18632/oncotarget.16646 |
Ejemplares similares
-
Monoamine oxidase-A activity is required for clonal tumorsphere formation by human breast tumor cells
por: Gwynne, William D., et al.
Publicado: (2019) -
Antagonists of the serotonin receptor 5A target human breast tumor initiating cells
por: Gwynne, William D., et al.
Publicado: (2020) -
Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer
por: Hallett, Robin M., et al.
Publicado: (2016) -
A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer
por: Hallett, Robin M., et al.
Publicado: (2012) -
Hormone Receptor and ERBB2 Status in Gene Expression Profiles of Human Breast Tumor Samples
por: Dvorkin-Gheva, Anna, et al.
Publicado: (2011)